Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (24779)	10/4/2007 11:44:56 PM
From: Ian@SI	of 52153

I looked at them briefly during the past year (Think I posted some stuff on this thread around which there was a bit of discussion.) At that time they did not have a PhIII underway in the US, they didn't have much cash I came to the conclusion that there was likely to be several secondaries and a long time before there was any NDA filed. Their mkt cap is quite small considering the drug's potential if successful, but so far I've taken a pass. It seems to me there are many better opportunities out there. Why take the risk with an undercapitalized, one drug pipeline company? Ian

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next